# Epcoritamab: First Approval

Source: https://onco.cc/key-papers/paper-epcoritamab-dlbcl-drugs-2023/  
OnCo record `paper-epcoritamab-dlbcl-drugs-2023` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Review on Epcoritamab in Diffuse large B-cell lymphoma, in Drugs (2023), one of the most cited Europe PMC records with Epcoritamab in its title.

## Summary

Epcoritamab (epcoritamab-bysp; Epkinly™; Tepkinly ®) is a subcutaneously administered CD3×CD20 T-cell-engaging bispecific antibody being co-developed by Genmab and AbbVie for the treatment of mature B-cell non-Hodgkin lymphoma subtypes (B-NHLs), including diffuse large B-cell lymphoma (DLBCL). Epcoritamab received its first (conditional) approval on 19 May 2023, in the USA, for the treatment of adult patients with relapsed or refractory (R/R) DLBCL, not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after ≥ 2 lines of systemic therapy. Elsewhere, epcoritamab has received a positive opinion in the EU as a monotherapy for the treatment of adults with R/R DLBCL after ≥ 2 lines of systemic therapy, and is currently under regulatory review in Japan for the treatment of adults with R/R large B-cell lymphoma after ≥ 2 lines of systemic therapy. Clinical development of epcoritamab as monotherapy and in combination with standard of care agents for the treatment of mature B-NHLs is ongoing globally. This article summarizes the milestones in the development of epcoritamab leading to this first approval for R/R DLBCL.

Indexed on Europe PMC as PubMed record 37597091 (DOI 10.1007/s40265-023-01930-4). Its title names Epcoritamab and its text names Diffuse large B-cell lymphoma; PubMed types it as a review (Review). It was matched automatically to the idea "ctDNA-guided escalation and de-escalation in frontline DLBCL" and no figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: Drugs
- Year: 2023
- DOI: 10.1007/s40265-023-01930-4
- Authors: Frampton JE
- What it means: One of the most cited reviews Europe PMC returns for Epcoritamab in Diffuse large B-cell lymphoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
- Caveats: Matched by Epcoritamab in the title and Diffuse large B-cell lymphoma in the title or abstract of the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.; A review summarises other studies; the primary reports it cites are the evidence.

## Sources

- Drugs 2023: https://doi.org/10.1007/s40265-023-01930-4
- PubMed: https://pubmed.ncbi.nlm.nih.gov/37597091/
- Europe PMC: https://europepmc.org/article/MED/37597091

## Connected records

- ideas: [ctDNA-guided escalation and de-escalation in frontline DLBCL](https://onco.cc/ideas/idea-ctdna-guided-dlbcl-frontline/)

---
JSON: https://onco.cc/api/v1/entities/paper-epcoritamab-dlbcl-drugs-2023.json